Epilepsy of infancy with migrating focal seizures (EIMFS) is a rare, severe developmental and epileptic encephalopathy in which frequent focal seizures begin in infancy and the ictal EEG shows seizure activity migrating between different cortical regions during the same seizure.
It is one of the most drug-resistant epilepsy syndromes of infancy and is strongly associated with genetic causes, particularly gain-of-function variants in KCNT1.
The defining EEG feature
The word “migrating” has a specific electrophysiological meaning. During one seizure, rhythmic ictal activity begins in one cortical region and then shifts to another region, sometimes moving between hemispheres.
This is different from having separate seizures that begin in different places on different occasions.
Age at onset
Seizures usually begin in the first months of life.
Some infants have seizures from the neonatal period, while others begin later in early infancy.
Seizure burden
Seizures can become extremely frequent, sometimes occurring many times per day.
Autonomic features such as flushing, apnoea or changes in heart rate can accompany focal motor manifestations.
Development
Developmental slowing or regression is typical. Severe developmental impairment is common as the disorder evolves.
The underlying genetic disorder and the extraordinary seizure burden are both likely to contribute.
EEG between seizures
The interictal EEG becomes increasingly abnormal over time and may show multifocal epileptiform discharges and background slowing.
Burst suppression or hypsarrhythmia can occur in atypical cases, but these are not the defining EEG feature.
MRI
Early MRI may be normal or show non-specific abnormalities.
Progressive cerebral atrophy and abnormalities of myelination have been reported later in some children.
KCNT1
KCNT1 is the most common identified gene and accounts for a substantial proportion of genetically solved EIMFS cases.
Pathogenic variants are usually gain-of-function, increasing activity of a sodium-activated potassium channel.
Other genes
EIMFS is genetically heterogeneous. More than 30 genes have been reported, including genes involved in ion channels and synaptic function.
Recent reviews estimate that genetic testing identifies a cause in a large majority of cases, making rapid genomic investigation a high priority.
Why rapid genetic testing matters
The diagnosis can influence treatment selection and access to experimental precision approaches.
It also prevents repeated low-yield investigations and provides families with recurrence-risk information.
Treatment difficulty
Seizures are commonly highly drug resistant. Multiple antiseizure medicines are often tried.
No universally effective treatment has been established.
Potassium bromide
Potassium bromide has shown benefit in some reported EIMFS cases and remains used in selected specialist centres and countries.
Availability varies considerably worldwide and adverse effects require monitoring.
Ketogenic dietary therapy
Ketogenic therapy can reduce seizure burden in some children but is not uniformly effective.
Because these infants are medically complex, treatment requires specialist metabolic and dietetic support.
Quinidine and KCNT1
Quinidine was investigated because it can inhibit KCNT1 channels in laboratory systems.
Clinical response has been inconsistent, and cardiac toxicity plus variable brain penetration limit its use. It should not be portrayed as an established standard treatment.
Emerging precision therapies
Research is moving toward genotype-specific treatment, including novel KCNT1-targeted molecules and nucleic-acid therapies.
These approaches remain investigational and are not yet routine clinical care.
SCN2A-related EIMFS
Selected early-onset SCN2A gain-of-function epilepsies can produce an EIMFS phenotype.
Sodium-channel blockers may be particularly relevant in those cases, illustrating why the exact gene and functional mechanism matter.
Cardiorespiratory complications
Recent literature has highlighted systemic-to-pulmonary collateral circulation and other serious cardiorespiratory complications in some children with EIMFS.
There is not yet a universal screening protocol, but the finding reinforces that EIMFS can be a multisystem clinical problem rather than only a seizure disorder.
Prognosis
Developmental disability is usually severe and mortality risk is increased.
Outcome varies by genetic cause, seizure control and associated systemic complications.
Worldwide access
EIMFS is especially difficult to diagnose without prolonged video-EEG and rapid genomic testing. In lower-resource settings, migrating ictal activity may never be documented.
Access to ketogenic therapy, uncommon medicines and genetic counselling is also unequal.
The central point
EIMFS is defined by seizure activity that migrates between cortical regions during the same seizure. It is a severe genetic epilepsy syndrome in which rapid molecular diagnosis is increasingly important for treatment and research access.
Related reading
Epilepsy Syndromes →
Genetic Testing in Epilepsy →
Early Infantile DEE →
Sources
- ILAE — neonatal and infant epilepsy syndromes
- 2026 scoping review — EIMFS clinical features, genetics, outcomes and emerging therapies
Medical note: precision treatments discussed for EIMFS are genotype-specific and many remain investigational.
Evidence checked: September 2026.